You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 141 No. 12, December 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Study
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (74)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Dermatologic Disorders
 •Public Health
 •Obesity
 •Psoriasis
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Impact of Obesity and Smoking on Psoriasis Presentation and Management

Mark D. Herron, MD; Michael Hinckley, BA; Matthew S. Hoffman, BS; Jason Papenfuss, MD; Christopher B. Hansen, MD; Kristina P. Callis, MD; Gerald G. Krueger, MD

Arch Dermatol. 2005;141:1527-1534.

Objective  To study the impact of obesity and smoking on psoriasis.

Design  Cross-sectional study.

Setting  University of Utah Department of Dermatology clinics.

Patients  A case series of patients with psoriasis enrolled in the prospective Utah Psoriasis Initiative (UPI) (which carefully performs phenotyping of patients with psoriasis) was compared with 3 population databases: the Behavioral Risk Factor Surveillance System of the Utah population, the 1998 patient-member survey from the National Psoriasis Foundation, and 500 adult patients who attend our clinics and do not have psoriasis (nonpsoriatic population).

Results  The prevalence of obesity in patients within the UPI population was higher than that in the general Utah population (34% vs 18%; P<.001) and higher than that in the nonpsoriatic population attending our clinics. Assessment of body image perception with a standardized diagram in the UPI group resulted in the median body image score of normal weight at 18 years of age and the onset of psoriasis, but it transitioned to overweight at the time of enrollment in the UPI. Thus, obesity appears to be the consequence of psoriasis and not a risk factor for onset of disease. We did not observe an increased risk for psoriatic arthritis in patients with obesity; furthermore, obesity did not positively or negatively affect the response or the adverse effects of topical corticosteroids, light-based treatments, and systemic medications. The prevalence of smoking in the UPI population was higher than in the general Utah population (37% vs 13%; P<.001) and higher than in the nonpsoriatic population (37% vs 25%; P<.001). We found a higher prevalence of smokers in the obese population within the UPI than in the obese population within the Utah population (25% vs 9%; P<.001).

Conclusions  Patients with psoriasis attending the University of Utah Dermatology Clinics were more likely to be obese and to smoke compared with nonpsoriatic patients and more likely to be obese compared with other large cohorts with psoriasis. Smoking appears to have a role in the onset of psoriasis, but obesity does not. The high prevalence of obesity and smoking in a psoriasis cohort has not been previously noted; if confirmed, it supports the prediction that a significant portion of patients with psoriasis will have the comorbid conditions and public health issues of those with obesity and smoke.


Author Affiliations: Departments of Dermatology, University of Utah School of Medicine, Salt Lake City (Messrs Hinckley and Hoffman and Drs Callis and Krueger), Medical University of South Carolina, Charleston (Dr Papenfuss), and The University of Texas Southwestern Medical Center, Dallas (Dr Hansen). Dr Herron is in private practice in Montgomery, Ala.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Obesity, Smoking, and Psoriasis
Mark Lebwohl and Jeffrey P. Callen
JAMA. 2006;295(2):208-210.
EXTRACT | FULL TEXT  

Prevalence and Treatment of Psoriasis in the United Kingdom: A Population-Based Study
Joel M. Gelfand, Rachel Weinstein, Steven B. Porter, Andrea L. Neimann, Jesse A. Berlin, and David J. Margolis
Arch Dermatol. 2005;141(12):1537-1541.
ABSTRACT | FULL TEXT  

Targeted UV-B Phototherapy for Plaque-type Psoriasis
Pravit Asawanonda, Akkrawat Chingchai, and Pawinee Torranin
Arch Dermatol. 2005;141(12):1542-1546.
ABSTRACT | FULL TEXT  

Dose-Response and Time-Course Characteristics of UV-A1 Erythema
Paula E. Beattie, Robert S. Dawe, James Ferguson, and Sally H. Ibbotson
Arch Dermatol. 2005;141(12):1549-1555.
ABSTRACT | FULL TEXT  

Soak and Smear: A Standard Technique Revisited
Ari Benjamin Gutman, Albert M. Kligman, Joslyn Sciacca, and William D. James
Arch Dermatol. 2005;141(12):1556-1559.
ABSTRACT | FULL TEXT  

Relationship Between Smoking and the Clinical Severity of Psoriasis
Cristina Fortes, Simona Mastroeni, Karen Leffondré, Francesca Sampogna, Franco Melchi, Eva Mazzotti, Paolo Pasquini, Damiano Abeni, and for the IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Study Group
Arch Dermatol. 2005;141(12):1580-1584.
ABSTRACT | FULL TEXT  

Advances in Psoriasis
Mark G. Lebwohl
Arch Dermatol. 2005;141(12):1589-1590.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Clinical Aspects and Comorbidities of Psoriasis
AYALA and AYALA
The Journal of Rheumatology Supplement 2009;83:19-20.
ABSTRACT | FULL TEXT  

Psoriasis Independently Associated With Hyperleptinemia Contributing to Metabolic Syndrome
Chen et al.
Arch Dermatol 2008;144:1571-1575.
ABSTRACT | FULL TEXT  

Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial
Gisondi et al.
Am. J. Clin. Nutr. 2008;88:1242-1247.
ABSTRACT | FULL TEXT  

Etanercept Treatment for Children and Adolescents with Plaque Psoriasis
Paller et al.
NEJM 2008;358:241-251.
ABSTRACT | FULL TEXT  

The Risk of Mortality in Patients With Psoriasis: Results From a Population-Based Study
Gelfand et al.
Arch Dermatol 2007;143:1493-1499.
ABSTRACT | FULL TEXT  

Incidence and Risk Factors for Psoriasis in the General Population
Huerta et al.
Arch Dermatol 2007;143:1559-1565.
ABSTRACT | FULL TEXT  

Obesity, Waist Circumference, Weight Change, and the Risk of Psoriasis in Women: Nurses' Health Study II
Setty et al.
Arch Intern Med 2007;167:1670-1675.
ABSTRACT | FULL TEXT  

Risk of myocardial infarction in patients with psoriasis.
Gelfand et al.
JAMA 2006;296:1735-1741.
ABSTRACT | FULL TEXT  

Psychiatric implications of psoriasis.
Skolnick and Alexander
JAMA 2006;295:2249-2250.
FULL TEXT  

Psychiatric Implications of Psoriasis--Reply
Lebwohl and Callen
JAMA 2006;295:2250-2250.
FULL TEXT  

Obesity, Smoking, and Psoriasis
Lebwohl and Callen
JAMA 2006;295:208-210.
FULL TEXT  

Advances in Psoriasis
Lebwohl
Arch Dermatol 2005;141:1589-1590.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.